Targets › CSFL3
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: the race on CSFL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Glycosylated Recombinant Human G-CSF AVI-014 G-CSF receptor agonist | CSFL3 | Phase 1 | Secondary Myelofibrosis | Apr 2027 |
Secondary Myelofibrosis (1)
mixed (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.